Omega Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€6.97M - Cost of goods sold
€11.15M - Gross profit
-€4.17M - SG&A expenses
€18.92M - R&D expenses
€48.84M - EBITDA
-€59.56M - D&A
€3.63M - EBIT
-€63.88M - Interest expenses
€0.00 - EBT
-€62.97M - Tax expenses
€5.01M - Net income
-€62.97M
Cash flow statement
- Net deferred tax
-€10.50M - Non-cash items
€12.39M - Changes in working capital
€1.42M - Operating cash flow
-€47.89M - Capex
€1.77M - Other investing cash flow
€7.11M - Net investing cash flow
€5.34M - Total cash dividends paid
€0.00 - Issuance of common stock
€22.40K - Debt repayment
-€3.15M - Other financing cash flow
€1.42M - Net financing cash flow
-€1.72M - Foreign exchange effects
-€23.46M - Net change in cash
-€44.28M - Cash at end of period
€26.47M - Free cash flow
-€46.11M
Balance sheet
- Cash and cash equivalents
€26.17M - Cash and short-term investments
€26.17M - Total receivables
€418.71K - Inventory
€0.00 - Other current assets
€6.97M - Total current assets
€33.56M - Property, plant & equipment
€98.00M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€26.71K - Total non-current assets
€98.02M - Total assets
€131.58M - Accounts payable
€1.24M - Short-term debt
€13.71M - Other current liabilities
€5.88M - Total current liabilities
€20.83M - Long-term debt
€96.68M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€4.13M - Total non-current liabilities
€100.81M - Total liabilities
€121.64M - Common stock
€47.39K - Retained earnings
-€333.86M - Other equity
€0.00 - Total equity
€9.94M - Total liabilities and shareholders' equity
€131.58M
Company information
- Market capitalization
€6.73M - Employees
93 - Enterprise Value
€105.65M
Company ratios
- Gross margin
-
-59.8% Much better than peer group: -3,688.6% - EBITDA margin
-
-854.0% Much better than peer group: -26,844.8% - EBIT margin
-
-916.0% Much better than peer group: -41,832.2% - EBT margin
-
-902.9% Much better than peer group: -737,795.2% - Net margin
-
-902.9% Much better than peer group: -26,926.6% - ROE
-
-633.2% Much worse than peer group: 43.9% - ROA
-
-47.9% Much better than peer group: -10,340.5% - Asset turnover
-
5.3% Much worse than peer group: 56.7% - FCF margin
-
-712.0% Much better than peer group: -62,745.9% - FCF yield
-737.4% - Efficiency ratio
954.0% - Net sales per employee
-
€74.99K - Net income per employee
-
-€677.12K